A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil

BACKGROUND: Numerous pathways can lead to erectile dysfunction (ED) in patients, with some patients having multiple causes. Regardless of the etiology, ED has been successfully treated in many patients with the advent of oral phosphodiesterase-5 inhibitors (PDE5Is). With the release of avanafil, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Jeffery D, Hill, Stephen R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542406/
https://www.ncbi.nlm.nih.gov/pubmed/26316720
http://dx.doi.org/10.2147/PPA.S56002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542406/
https://www.ncbi.nlm.nih.gov/pubmed/26316720
http://dx.doi.org/10.2147/PPA.S56002

Ejemplares similares